Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • Dow

    38,852.27
    +176.59 (+0.46%)
     
  • Nasdaq

    16,349.25
    +192.92 (+1.19%)
     
  • Bitcoin USD

    64,231.96
    -936.93 (-1.44%)
     
  • CMC Crypto 200

    1,333.77
    -31.36 (-2.30%)
     
  • FTSE 100

    8,298.31
    +84.82 (+1.03%)
     
  • Gold

    2,324.20
    -7.00 (-0.30%)
     
  • Crude Oil

    78.54
    +0.06 (+0.08%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop

AbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug Humira. AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting the biopharmaceutical company to post full-year earnings of $11.12 a share.